[ad_1]
ISR Immune System Regulation Holding is a pharmaceutical and research company in immunotherapy. Since 2012, they have been working on a broad front to combat some of the world’s most notorious diseases, including HIV, cancer, and hepatitis B. A recent new issue shows great interest from investors.
The Swedish ISR, based at the Karolinska Institutet in Stockholm, began with a discovery of the animal world. ISR found that neutered cats infected with IVF, the equivalent of HIV, survived to a significantly greater degree, as opposed to non-neutered cats affected by the virus.
– Castration of cats causes the extinction of the production of sex hormones. The brain system then produces the substance GnRH, a small molecule of great importance. It stimulates the release of sex hormones, but also activates important parts of the immune system so that the infection begins to be treated, says Ola Winqvist, CEO of ISR.
EXTERNAL LINK: Curious about ISR technology? read more here
Ongoing treatment studies
This information laid the foundation for ISR, which today develops the next generation of immunostimulatory drug candidates.
– The GnRH hormone has been on the market for more than 30 years and is used against prostate cancer, among other things. The virus is then exposed to the immune system that can kill the infected cell, says Ola Winqvist.
Treatment studies are currently underway in hospitals in Stockholm and Gothenburg on whether HIV patients receiving antiretroviral medication can reduce the amount of integrated virus and possibly cure the disease.
– Once the corona pandemic has subsided, we will also start a study in Berlin with infected patients resistant to antiretroviral drugs. Species resistance affects up to 14 percent of people living with HIV. This is a major problem that puts the patient at risk of further developing AIDS. We see this as an introduction to the market where time to market is considered very short, says Ola Winqvist.
EXTERNAL LINK: Learn more about the company’s work with drugs for the HIV market
Strong financial platform
The most recent ISR rights issue, which ended on May 29, provided the company with approximately SEK 71.7 million. It provides them with a solid financial platform for future research and shows that investors have good faith in the company’s development work.
– We are on several legs: HIV, cancer, hepatitis B and, more recently, a vaccine against the coronavirus. In other words, we have a development portfolio with great potential and studies that need refinancing. Those who have chosen to get into this see, as do we, a number of opportunities that will soon open up, says Lennart Dreyer, ISR’s chief operating officer, and concludes:
– We want to thank both the new shareholders and the previous shareholders for the trust we have received. There is a large market in both the east and west waiting for us. In China, for example, 100 million people have hepatitis B and our arthritis study will most likely be interesting for the US market – an exciting portfolio, to say the least!
ISR data
ISR Immune System Regulation Holding AB is an innovation-driven research company with a focus on the immune system, based at Karolinska Institutet in Stockholm. The company develops immunostimulatory drugs to treat chronic infectious diseases and cancer by activating its own immune system. ISR is currently conducting several important studies, both in terms of HIV and cancer, which may be of great importance for future treatments. EXTERNAL LINK: read more here
